SGSrikanta Goswami

Srikanta Goswami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Srikanta Goswami has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Moumita Mukherjee

    Biotechnology Research and Innovation Council, National Institute of Biomedical Genomics (BRIC-NIBMG), 741251, Kalyani, India

    7 shared publications
  • Bishnupriya Chhatriya

    National Institute of BioMedical Genomics, Kalyani, West Bengal 741251, India

    5 shared publications
  • Sukanta Ray

    Institute of Postgraduate Medical Education & Research, Kolkata 700020, WB, India

    5 shared publications
  • Barsha Saha

    Biotechnology Research Innovation Council-National Institute of Biomedical Genomics (BRIC-NIBMG), Kalyani 741251, WB, India; Regional Centre for Biotechnology, 3rd Milestone, Faridabad-Gurugram Expressway, Faridabad 121001, India

    4 shared publications
  • Kshaunish Das

    Institute of Postgraduate Medical Education & Research, Kolkata 700020, WB, India

    4 shared publications
  • Hemabha Saha

    Institute of Postgraduate Medical Education & Research, Kolkata 700020, WB, India

    3 shared publications

Latest Publications

  • Open Access

    Molecular hydrogen in cancer: reprogramming oncogenic signaling pathways and emerging pharmacological potential

    by Anirban Kumar Maity, Ajay Mallick, Debbie C. Crans, Srikanta Goswami, Soumyajit Roy

    Molecular hydrogen (H 2 ) is a chemically inert, non-toxic, highly diffusible gas that has recently attracted considerable interest as a novel bioactive mediator with growing therapeutic relevance in oncology. Emerging evidence suggests that H 2 modulates multiple pathways involved in cancer initiation and progression, including attenuation of oncogenic signaling, suppression of metastatic dissemination, enhancement of therapeutic responsiveness, and regulation of epigenetic, mitochondrial, and immune-associated oncogenic programs. Beyond its antioxidant activity, H 2 has been shown to partially reprogram cancer-associated epigenetic modifications, restore dysregulated proteostatic pathways, and attenuate oxidative stress–driven cellular injury, collectively contributing to reduced tumor cell survival and enhanced therapeutic sensitivity. Recent preclinical studies demonstrate that H 2 exerts anticancer effects through coordinated regulation of epigenetic remodeling, mitochondrial stress and proteostasis, tumor suppressive cell death and cell-cycle arrest, and immunomodulation with metastatic restraint. Specifically, H 2 influences histone methylation dynamics and oncogenic non-coding RNA signaling, activates mitochondrial stress and unfolded protein response pathways, induces cell-cycle arrest and inflammatory tumor cell death, and suppresses metastatic behavior through the downregulation of key proliferation and immune evasion associated mediators. In parallel, H 2 based interventions have been shown to enhance antitumor immune responses by modulating CD8 + T-cell activity, apoptosis related regulators and tumor suppressor signaling across hepatocellular and lung cancer models. Collectively, these findings position H 2 as a pharmacologically versatile adjuvant with the capacity to enhance conventional anticancer therapies while mitigating oxidative and inflammatory tissue injury. However, further mechanistic studies and clinical validation are required for its effective translation into oncologic practice.

  • Identification of circulating microRNA signature in pancreatic ductal adenocarcinoma and chronic pancreatitis patients from Indian population

    by Barsha Saha, Sushmita Ghosal, Shouvik Chakravarty, Sukanta Ray, Hemabha Saha, Kshaunish Das, Sourav Manna, Arghya Bandyopadhyay, Utpal De, Indranil Ghosh, et al.

  • Open Access

    LncRNA CASC19 promotes pancreatic cancer progression by increasing PSPC1 protein stability and facilitating the oncogenic PSPC1/ β-Catenin pathway

    by Moumita Mukherjee, Swati Ghosh, Atanu Maity, Sukanta Ray, Hemabha Saha, Ranjit Prasad Bahadur, Srikanta Goswami

    Background: Pancreatic cancer, a highly lethal malignancy, is influenced by complex lncRNA-mediated gene expression. This study identified CASC19 as a significantly overexpressed lncRNA with high oncogenic potential in pancreatic cancer, aiming to uncover its molecular mechanism in tumor progression. Methods: CASC19 expression was evaluated by qRT-PCR. Proliferation abilities of CASC19 were evaluated by MTT assay, cell cycle and apoptosis assay, upon CASC19 overexpression and knockdown. Whereas its metastatic potential was evaluated by wound healing, migration and invasion assay. The effect of CASC19 on cellular transcriptome was also examined by RNA sequencing after CASC19 overexpression and silencing. Subcellular localization of the lncRNA was examined by subcellular fractionation followed by qRT-PCR. To find out the molecular mechanism of lncRNA function, RNA-pull down, mass-spectrometry, immunoprecipitation, protein stability and ubiquitination assays were done. Results: High CASC19 expression was found in pancreatic tumor tissues and multiple pancreatic cancer cell lines. In-vitro loss and gain-of-function experiments showed that CASC19 is an oncogenic lncRNA promoting proliferation and metastasis of pancreatic cancer, while inhibiting apoptosis. CASC19 was also found to regulate global transcriptome of pancreatic cancer cells, affecting pathways like TGF-β signaling pathway, β-Catenin-TCF complex assembly, etc. CASC19 was localized to nucleus of pancreatic cancer cells and was identified to interact with PSPC1, a metastatic reprogramming protein. The interaction results in prevention of ubiquitin-mediated degradation of PSPC1. Increased availability of PSPC1, in turn, potentiates nuclear retention of β-Catenin which ultimately triggers pancreatic cancer progression. Conclusion: Our findings elaborate the mechanism of CASC19 mediated tumorigenesis in pancreatic cancer, highlighting the role of PSPC1 in the process. Targeting CASC19/PSPC1/β-Catenin axis could be a novel approach to impede the progression of the disease.


  • Open Access

    Dynamic interaction of MYC enhancer RNA with YEATS2 protein regulates MYC gene transcription in pancreatic cancer

    by Jayita Roy, Aniket Kumar, Shouvik Chakravarty, Nidhan K Biswas, Srikanta Goswami, Anup Mazumder

    Pancreatic ductal adenocarcinoma (PDAC) is one of the most prevalent and aggressive forms of pancreatic cancer with low survival rates and limited treatment options. Aberrant expression of the MYC oncogene promotes PDAC progression. Recent reports have established a role for enhancer RNAs (eRNAs), originating from active enhancers, in controlling gene transcription. Here we show that a novel MYC eRNA regulates MYC gene expression during chronic inflammatory conditions in pancreatic cancer cells. A higher amount of MYC eRNA is observed in chronic pancreatitis and in pancreatic cancer patients. We show that MYC eRNA interacts with YEATS2, a histone reader protein of the ATAC-HAT complex, and augments the association of YEATS2-containing ATAC complexes with MYC promoter/enhancer regions and thus increases MYC gene expression. TNF-α induced Tyrosine dephosphorylation of the YEATS domain increases MYC eRNA binding to the YEATS2 protein in pancreatic cancer cells. Our study adds another regulatory layer of MYC gene expression by enhancer-driven transcription.


  • Open Access

    Differential Expression of miRNAs Between Young-Onset and Late-Onset Indian Colorectal Carcinoma Patients

    by Sumaiya Moiz, Barsha Saha, Varsha Mondal, Debarati Bishnu, Biswajit Das, Bodhisattva Bose, Soumen Das, Nirmalya Banerjee, Amitava Dutta, Krishti Chatterjee, et al.

    Reports indicate a worldwide increase in the incidence of Early-Onset Colorectal Carcinoma (EOCRC) (APC mutations, as these are known canonical factors in CRC pathogenesis. Small-RNA sequencing followed by comparative analysis revealed differential expression of 23 miRNAs (microRNAs) specific to EOCRC and 11 miRNAs specific to LOCRC. We validated the top 10 EOCRC DEMs in TCGA-COAD and TCGA-READ cohorts, followed by validation in additional EOCRC and LOCRC cohorts. Our integrated analysis revealed upregulation of hsa-miR-1247-3p and hsa-miR-148a-3p and downregulation of hsa-miR-326 between the two subsets. Experimentally validated targets of the above miRNAs were compared with differentially expressed genes in the TCGA dataset to identify targets with physiological significance in EOCRC development. Our analysis revealed metabolic reprogramming, downregulation of anoikis-regulating pathways, and changes in tissue morphogenesis, potentially leading to anchorage-independent growth and progression of epithelial-mesenchymal transition (EMT). Upregulated targets include proteins present in the basal part of intestinal epithelial cells and genes whose expression is known to correlate with invasion and poor prognosis.


  • Open Access

    Correlating tissue and plasma‑specific piRNA changes to predict their possible role in pancreatic malignancy and chronic inflammation

    by Barsha Saha, Shouvik Chakravarty, Sukanta Ray, Hemabha Saha, Kshaunish Das, Indranil Ghosh, Bibekanand Mallick, Nidhan K. Biswas, Srikanta Goswami

    The aggressiveness of pancreatic ductal adenocarcinoma is primarily due to lack of effective early detection biomarkers. Circulating non‑coding RNAs serve as diagnostic or prognostic biomarkers in multiple types of cancer. Comparison of their expression between diseased tissue and relevant body fluids such as saliva, urine, bile, pancreatic juice, blood etc. may reveal mechanistic involvement of common non‑coding RNAs. piwi‑interacting RNAs (piRNAs) are a class of non‑coding RNAs. The aim of the present study was to investigate plasma and tumour tissue piRNA changes in patients with pancreatic cancer (PC) and explore the possible role in tumorigenesis and pancreatic inflammation. Sequencing of circulating plasma small RNAs from patients with PC and chronic pancreatitis (CP) was performed and differentially expressed piRNAs were compared with those in tissues. Subsequent search for target genes for those piRNAs was performed followed by pathway and cluster analysis. A total of 36 piRNAs were shown to be deregulated in pancreatic tumour tissue and alteration of 11 piRNAs was detected in plasma of patients with PC. piRNAs hsa‑piR‑23246, hsa‑piR‑32858 and hsa‑piR‑9137 may serve a key role in PC development as their expression was correlated in both plasma and tumour tissue. Key piRNA‑target interactions interfering with key biological pathways were also characterized. A total of 19 deregulated piRNAs in plasma samples of patients with CP was identified; these targeted genes responsible for chronic inflammation. Therefore, the present study provides a comprehensive description of piRNA alteration in pancreatic malignancy and inflammation; these may be explored for biomarker potential in future.


  • Open Access

    Differential expression of miRNAs between Young-Onset and Late-Onset Indian colorectal carcinoma patients

    by Sumaiya Moiz, Varsha Mondal, Debarati Bishnu, Biswajit Das, Bodhisattva Bose, Soumen Das, Nirmalya Banerjee, Amitava Dutta, Krishti Chatterjee, Srikanta Goswami, et al.

    Early-Onset Colorectal Carcinoma (EOCRC) is a growing concern as reports indicate a worldwide increase in the incidence of CRC among young adults (55 years old) and screened them to eliminate tumors positive for Microsatellite Instability (MSI) and showing activation of the Wnt pathway, known canonical factors in CRC pathogenesis. RNA isolated from EOCRC and Late-Onset (LOCRC) tumors and paired normal tissues without MSI, nuclear β-catenin and APC mutations were sent for small RNA seq to identify miRNA alterations between the two subsets. Comparative analysis revealed differential expression of 23 miRNAs specific to EOCRC and 11 miRNAs specific to LOCRC. We validated the top 10 EOCRC DEMs in TCGA-COAD cohorts followed by validation in additional EOCRC and LOCRC cohorts. Our integrated analysis revealed upregulation of hsa-miR-1247-3p, hsa-miR-148a-3p and hsa-miR-27a-5p and downregulation of hsa-miR-326 between the two subsets. Experimentally validated targets of the above miRNAs were compared with differentially expressed genes in the TCGA dataset to identify targets with physiological significance in EOCRC development. Our analysis revealed downregulation of epithelial gene expression and intercellular junction proteins potentially leading to dissolution of epithelial intercellular junctions in EOCRC development and EMT progression. Upregulated targets included genes whose expression have been reported to correlate with CRC tumor invasion, liver metastasis, disease recurrence and poor prognosis.

  • Open Access

    Identification of Key Deregulated RNA-Binding Proteins in Pancreatic Cancer by Meta-Analysis and Prediction of Their Role as Modulators of Oncogenesis

    by Moumita Mukherjee, Srikanta Goswami

    RNA-binding proteins (RBPs) play a significant role in multiple cellular processes with their deregulations strongly associated with cancer. However, there are not adequate evidences regarding global alteration and functions of RBPs in pancreatic cancer, interrogated in a systematic manner. In this study, we have prepared an exhaustive list of RBPs from multiple sources, downloaded gene expression microarray data from a total of 241 pancreatic tumors and 124 normal pancreatic tissues, performed a meta-analysis, and obtained differentially expressed RBPs (DE-RBPs) using the Limma package of R Bioconductor. The results were validated in microarray datasets and the Cancer Genome Atlas (TCGA) RNA sequencing dataset for pancreatic adenocarcinoma (PAAD). Pathway enrichment analysis was performed using DE-RBPs, and we also constructed the protein–protein interaction (PPI) network to detect key modules and hub-RBPs. Coding and noncoding targets for top altered and hub RBPs were identified, and altered pathways modulated by these targets were also investigated. Our meta-analysis identified 45 upregulated and 15 downregulated RBPs as differentially expressed in pancreatic cancer, and pathway enrichment analysis demonstrated their important contribution in tumor development. As a result of PPI network analysis, 26 hub RBPs were detected and coding and noncoding targets for all these RBPs were categorized. Functional exploration characterized the pathways related to epithelial-to-mesenchymal transition (EMT), cell migration, and metastasis to emerge as major pathways interfered by the targets of these RBPs. Our study identified a unique meta-signature of 26 hub-RBPs to primarily modulate pancreatic tumor cell migration and metastasis in pancreatic cancer. IGF2BP3, ISG20, NIP7, PRDX1, RCC2, RUVBL1, SNRPD1, PAIP2B, and SIDT2 were found to play the most prominent role in the regulation of EMT in the process. The findings not only contribute to understand the biology of RBPs in pancreatic cancer but also to evaluate their candidature as possible therapeutic targets.